Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecu

• click to rate

  Posted by Two Blokes Jun 18 - Filed in Stock - 3 views
  
  -  T he Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis. -  Preclinical data, including higher oral exposure, longer half-life and strong efficacy, support ASC50 as a potential best-in-class once-daily oral agent for the treatment of psoriasis.